profit from every $100 of sales.
$0$100
BridgeBio Oncology Therapeutics
$2.14-8.94% today
-84.1% in 1 year
1-year low $2.041-year high $13.69
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What BridgeBio Oncology Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2023 to $0 in 2025, with -$134 million of profit last year.
SalesProfit
BridgeBio Oncology Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| BridgeBio Oncology Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads BridgeBio Oncology Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| 0 | 0 | 0 | |
| – | – | – | |
| -65 | -81 | -146 | |
| -65 | -81 | -145 | |
| -65 | -74 | -134 | |
| -0.82 | -0.94 | -4.30 | |
| – | – | – | |
| – | – | – | |
| – | – | – |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 6 | 164 | 448 |
| Cash | 0 | 31 | 374 |
| Total debt | – | 0 | 3 |
| Total liabilities | 122 | 343 | 37 |
| -116 | -179 | 411 | |
| 70 | 79 | 31 | |
| – | – | -27.8% | |
| 55.9% | 41.6% | -32.6% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| -52 | -55 | -114 | |
| 0 | 0 | 1 | |
| -52 | -55 | -115 | |
| Dividends paid | – | – | – |
| – | – | – | |
| 16 | 4 | 6 |
Valuation
- –
- –
- –
- 0.7×
- –
- –
- –
- -66.7%
- -78.1%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -45.0%
- -198,345.0%
- -61.5%
- -36.9%
- -45.1%
- –
Growth
- –
- –
- −14,890.4%
- –
- +11.0%
Financial health
- 0.3×
- 0.01
- 0.6%
- –
- 6.16
- 6.16
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 7%of 963
Bottom 20%of 894
Bottom 1%of 991
What analysts expect
- Average price target
- $21.67
- Range
- $18.00 – $24.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.53 | -0.51 | −2.8% |
| Mar 5, 2026 | -0.48 | -0.63 | +24.2% |
| Nov 12, 2025 | -1.03 | -0.41 | −151.2% |
| Aug 1, 2025 | 0.04 | – | – |
| May 15, 2025 | -0.02 | – | – |
| Mar 11, 2025 | 0.12 | – | – |
| Nov 14, 2024 | 0.10 | – | – |
| Aug 14, 2024 | 0.09 | – | – |
News
BridgeBio reports improved symptoms in Phase 3 trial of rare-disease drugSeeking Alpha · Oct 11, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
71Pass
Philip Fisher
33No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
26No pass
Questions about BridgeBio Oncology Therapeutics
Is BridgeBio Oncology Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BridgeBio Oncology Therapeutics AI analysis
What does BridgeBio Oncology Therapeutics do?
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. It is in Biotechnology.
Does BridgeBio Oncology Therapeutics pay a dividend?
No. BridgeBio Oncology Therapeutics does not pay a dividend at the moment.
Is BridgeBio Oncology Therapeutics stock halal?
No. BridgeBio Oncology Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 218% of its market value, at or above the 33% limit. How we check
How has BridgeBio Oncology Therapeutics stock done over the past year?
Down 84.1% over the past twelve months, to $2.14. It traded between $2.04 and $13.69 and is 84.4% below its high.
Who are BridgeBio Oncology Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with BridgeBio Oncology Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.